Use in Adults and Children under Doctor Surpervision
Active Ingredient: Leuprorelin acetate
Prescription Product
Therapeutic indications of Prostap SR 3.75mg
(i) Metastatic prostate cancer.
(ii) Locally advanced prostate cancer, as an alternative to surgical castration.
(iii) As an adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
(iv) As an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression.
(v) As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
(vi) Management of endometriosis, including pain relief and reduction of endometriotic lesions.
(vii) Endometrial preparation prior to intrauterine surgical procedures including endometrial ablation or resection.
(viii) Preoperative management of uterine fibroids to reduce their size and associated bleeding.
The product is only available on prescription of a registered Doctor / Vet and other registered prescribers. You can order this product now, but it will not be shipped until we have received your valid prescription. Once you have ordered we will email you different ways to get your prescription to us.
£121.50Original price was: £121.50.£98.80Current price is: £98.80.
Introducing Prostap Injection 3.75mg DCS – Leuprorelin Injection, a versatile and effective treatment for a range of medical conditions. Prostap Injection 3.75mg is a man-made hormone that helps to reduce the levels of testosterone and estrogen in the body, making it an ideal treatment for prostate cancer, early-stage breast cancer, advanced breast cancer, and endometriosis.
In addition, Prostap Injection can also be used to treat premature puberty, which is caused by the release of certain hormones from the pituitary gland in girls under 9 years of age and boys under 10 years of age. This makes Prostap Injection an important treatment option for young patients who require hormone regulation.
Prostap Injection 3.75mg DCS – Leuprorelin Injection is a synthetic hormone that is easy to administer and has been proven to be effective in a range of clinical settings. It can also be used during IVF procedures, providing an additional option for couples undergoing fertility treatment.
If you or a loved one is facing any of these medical conditions, Prostap Injection 3.75mg DCS – Leuprorelin Injection may be an effective treatment option. Speak with your healthcare provider today to learn more about this powerful medication and whether it is right for you.
Prostap Injection 3.75mg DCS Reviews
After using Prostap Injection 3.75mg DCS, it’s helpful to let others know about your experience. Reviews of an item help other users know that medicines received have helped the condition it is claimed for, how well the treatment worked or any issues to be aware of. We invite our users to leave a review of both their treatment and of the service provided. Click on the reviews tab to see if there has been feedback on this item.
PROSTAP 3 should only be administered by your doctor or a nurse who will also take care of the preparation of the product.
The doctor or nurse will give you an injection of PROSTAP 3. The injection will normally be given in your arm, thigh or abdomen. The injection site should be varied at regular intervals.
You will normally be given an injection once every 3 months.
If you have early breast cancer, you will be given PROSTAP 3 every three months in combination with tamoxifen or an aromatase inhibitor. A minimum of one injection of PROSTAP 3 should be given before you start treatment with an aromatase inhibitor or tamoxifen.
If you have advanced breast cancer, you will be given PROSTAP 3 every three months as an add-on to your other breast cancer treatment.
If you have endometriosis you will be given an injection of PROSTAP 3 for a period of 6 months only and treatment will be initiated during the first five days of the menstrual cycle.
Use in children
Treatment of children should be under the overall supervision of the paediatric endocrinologist.
The dosing scheme needs to be adapted individually.
The recommended starting dose is dependent on the body weight:
a) Children with a body weight 20 kg or more
Unless prescribed otherwise, 1 ml PROSTAP 3 (11,25 mg leuprorelin acetate) is administered every 3 months under the skin of e.g. abdomen, bottom or thigh as a single injection.
b) Children with a body weight less than 20 kg
Taking into account the clinical activity of the central precocious puberty in these rare cases, the following applies:
Unless prescribed otherwise, 0,5 ml PROSTAP 3 (5,625 mg leuprorelin acetate) are administered every 3 months under the skin of e.g. abdomen, bottom or thigh as a single injection. The remainder of the suspension should be discarded. Your doctor will monitor the child’s weight gain.
Depending on the central precocious puberty activity, your doctor may increase the dosage in the presence of inadequate suppression (e.g. vaginal bleeding). Your doctor will determine the minimal effective dose with the help of a blood test.
The duration of treatment depends on the clinical signs at the start of treatment or during the course of treatment and is decided by your doctor together with the legal guardian and, if appropriate, the treated child. Your doctor will determine the bone age of the child in regular intervals.
In girls with bone maturation of older than 12 years and boys with bone maturation of older than 13 years your doctor will consider discontinuing the treatment, depending on the clinical effects in your child.
In girls, pregnancy should be excluded before the start of treatment. The occurrence of pregnancy during treatment cannot be generally excluded. In such cases, please talk to your doctor.
The therapy is a long-term treatment, adjusted individually. Please arrange with your doctor that PROSTAP 3 is administered as precisely as possible in regular 3-monthly periods. An exceptional delay of the injection date for a few days (90 ± 2 days) does not influence the result of the therapy.
If you miss an injection
As soon as you realise you have missed an injection, contact your doctor who will be able to give you your next injection.
Women only:
If a PROSTAP 3 injection is missed, breakthrough bleeding or ovulation may occur with the potential for conception. If you think you may be pregnant you should stop using PROSTAP 3 and contact your doctor immediately.
If you stop using PROSTAP 3
If you are being given PROSTAP 3 for the treatment of advanced or early breast cancer, you must not stop your treatment with PROSTAP 3 whilst you are taking an aromatase inhibitor. If you are going to discontinue treatment with PROSTAP 3, your aromatase inhibitor treatment must also be discontinued within 3 months of your last PROSTAP 3 injection.
Delivery Options
Delivery options
All deliveries are subject to the availability of the product and product sale conditions been met.
Order & Collect
Free next-day collection from In-Store
UK Delivery
Standard Delivery within the UK £3.50 Delivery time 3-4 days First Class Delivery within the UK £5.90 Delivery time 1-2 days Priority Delivery within the UK £7.10. Next day delivery by 1pm. Order must be placed by 1pm. Priority delivery is only available Monday to Thursday.
Europe Delivery
Standard Delivery within EEC from £12.50 Delivery time up to 5 days depending on the local delivery service within your country. Expedited Delivery within EEC £39.50 Delivery time 2 days. Delivery by DHL, UPS or TNT.
Rest of the World
Standard Delivery Rest of the World from £16.10 Delivery Time 10 – 15 Days Expedited Delivery Rest of the World £55.09 Delivery 5 days. Delivery service by DHL, TNT or UPS
Use in children: Your doctor will make a precise diagnosis of central precocious puberty.
Do not take PROSTAP 3:
If you are allergic (hypersensitive) to leuprorelin acetate (PROSTAP SR or PROSTAP 3) or any of the other ingredients of PROSTAP 3 (listed in section 6).
If you are pregnant, planning to become pregnant or are breastfeeding.
If you have abnormal vaginal bleeding which you have not discussed with your doctor.
In pre and perimenopausal women receiving PROSTAP 3 for the treatment of breast cancer:
your estrogen levels must have been adequately suppressed with PROSTAP 3 before you start treatment with an aromatase inhibitors such as exemestane and should be checked every three months during combination treatment with PROSTAP 3 and an aromatase inhibitor (see ‘Warnings and precautions’ section below for more information).
In girls with central precocious puberty
if the girl to be treated is pregnant or breast-feeding.
if the girl has undiagnosed vaginal bleeding.
Warnings and Precautions:
Both men and women:
If you are diabetic PROSTAP 3 can aggravate existing diabetes therefore diabetes patients may need more frequent monitoring of the blood glucose levels.
If you have diabetes or suffer from heart problems you should tell your doctor.If you are at an increased risk of thinning of the bones (osteoporosis) you should tell your doctor before taking PROSTAP 3. Risk factors include:
If you or any of your close family have thinning of the bones.
If you drink excessive amounts of alcohol, and/or smoke heavily.
If you take drugs for epilepsy or have taken steroids such as hydrocortisone or prednisolone for a long time.
There have been reports of depression in patients taking PROSTAP 3 which may be severe. If you are taking PROSTAP 3 and develop depressed mood, inform your doctor.
Women only:
If you are a woman with submucous fibroids (benign tumours in the muscle underneath the lining of the womb), PROSTAP 3 can cause severe bleeding when the fibroids break-down. Contact your doctor immediately if you experience severe or unusual bleeding or pain.
If you are a woman and continue to have periods (menstruate) after starting treatment with PROSTAP 3 you should tell your doctor.
If you are a woman of child-bearing age, you should use non hormonal contraception whilst receiving PROSTAP 3. Although PROSTAP 3 causes periods to stop, it is not itself a contraceptive. If you are unsure about this talk to your doctor.
If you are being given PROSTAP 3 for the treatment of breast cancer:
Your doctor may assess your bone density and ovarian function before you start treatment with PROSTAP 3 and monitor your bone density and ovarian function throughout treatment.
PROSTAP 3 must be started at least 6-8 weeks before you start treatment with an aromatase inhibitor and should continue throughout treatment with the aromatase inhibitor.
If you have had chemotherapy, PROSTAP 3 treatment should only commence once you have completed chemotherapy and pre-menopausal status has been confirmed.
The recommended duration of treatment with PROSTAP 3 in combination with other hormone treatments for breast cancer is up to 5 years.
If you are being given PROSTAP 3 in combination with an aromatase inhibitor, your doctor may monitor your blood pressure, heart function and blood glucose levels during treatment. If you have depression or a history of depression, please inform you doctor so that they can additionally monitor your symptoms of depression during treatment with PROSTAP 3.
If you are unsure about this, speak to your doctor.
Men only:
In the rare event of an abscess occurring at the injection site your doctor may measure your testosterone levels as there could be reduced absorption of leuprorelin from the injection site.
If you are a man with urinary obstruction or spinal cord compression. Your doctor will supervise you closely for the first few weeks of treatment.
If you are a man with prostate cancer, and have had injections of a synthetic hormone in the past that has not worked, or you have had an operation to remove your testicles you should tell your doctor.
Please tell your doctor if you have any of the following: Any heart or blood vessel conditions, including heart rhythm problems (arrhythmia), or are being treated with medicines for these conditions. The risk of heart rhythm problems may be increased when using PROSTAP 3.
In children:
In the event of a sterile abscess at the injection site (mostly reported after injection into the muscle) your doctor will monitor your hormone levels as there could be reduced absorption of leuprorelin from the injection site.
If the child has progressive brain tumour your doctor will decide if treatment with leuprorelin is appropriate.
In girls with central precocious puberty:
After the first injection vaginal bleeding (spotting) and discharge may occur as a sign of hormone withdrawal. Vaginal bleeding beyond the first/second month of treatment needs to be investigated.
Bone density may decrease during treatment of central precocious puberty with Leuprorelin 3 Month Depot. However, after treatment is stopped, subsequent bone mass growth is preserved and peak bone mass in late adolescence does not seem to be affected by treatment.
Often sterile abscesses at the injection site occurred when Leuprorelin 3 Month Depot is administered in higher dosages than recommended and when it is administered into the muscle. Your doctor will therefore administer the medicinal product under the skin of e.g. abdomen, bottom or thigh.
Discontinuation of treatment may lead to a slipping of the growth plate of the thigh bone. A possible cause could be a weakness of the growth plate due to a lower concentration of female sexual hormones during treatment.
Other medicines and PROSTAP 3
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
PROSTAP 3 might interfere with some medicines used to treat heart rhythm problems (e.g. quinidine, procainamide, amiodarone and sotalol) or might increase the risk of heart rhythm problems when used with some other drugs (e.g. methadone (used for pain relief and part of drug addiction detoxification), moxifloxacin (an antibiotic), antipsychotics used for serious mental illnesses).
PROSTAP 3 with food and drink
PROSTAP 3 can be taken with or without food.
Pregnancy and breastfeeding
Prostap 3 must not be administered in pregnant or breast-feeding women or girls (see also section “Do not use Prostap 3’).
Driving and using machines
Do not drive or operate machinery if you experience drowsiness, dizziness or visual disturbances whilst being treated with PROSTAP 3.
HOW TO STORE PROSTAP 3
Keep out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the packaging. The expiry date refers to the last day of that month.
Do not store above 25°C.
Do not refrigerate or freeze.
Store in the original container in order to protect from light.
Once mixed with the Sterile Solvent, the suspension must be used immediately.
If the pack has been opened or damaged, return it to your pharmacist.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
Side Effects
Like all medicines, PROSTAP 3 can cause side effects, although not everybody gets them.
Contact your doctor immediately or go to hospital:
If you develop a severe rash, itching or shortness of breath or difficulty breathing. These could be symptoms of a severe allergic reaction.
Tell your doctor:
If you get a severe headache which does not get better when you take painkillers.
If you suffer from any unexplained bruising or bleeding or feel generally unwell whilst taking PROSTAP 3. Although rare, these could be symptoms of changes in the number of red or white blood cells.
If any of the following side effects get serious, or if you notice any side effects not listed in this leaflet, speak to your doctor or pharmacist:
Men
When men with prostate cancer first start treatment with PROSTAP 3, levels of testosterone can increase and in some people this may cause a temporary increase in local pain. In some cases, to prevent this from happening, your doctor may give you another type of drug such as cyproterone acetate or flutamide before and just after your first PROSTAP 3 injection. If you do get worsening pain, weakness or loss of feeling in your legs or difficulty passing urine, contact your doctor immediately.
If you have an existing pituitary lesion, there may be an increased risk of loss of blood to the area, which may cause permanent damage. This is very rare (may affect more than 1 in 10,000 people).
Blood sugar levels may be altered during treatment with PROSTAP 3, which may affect control in diabetic patients and require more frequent monitoring.
If you have a blood test your doctor may notice a change in blood lipid (cholesterol) levels or in values for tests on how the liver is working. These changes do not usually cause any symptoms.
Very common (may affect more than 1 in 10 people)
Weight changes, hot flushes, sweating, muscle weakness, bone pain, loss of interest in sexual intercourse, inability to have an erection, a reduction in size and function of the testes, tiredness or skin reactions at the injection site (these include skin hardening, redness, pain, abscesses, swelling, nodules, ulcers and skin damage).
Common (may affect up to 1 in 10 people)
Loss of appetite, difficulty sleeping, depression, mood changes (with long-term use), headache, nausea, abnormalities in liver function or liver blood tests, joint pain, swelling of the breast tissue or swelling in your ankles.
Uncommon (may affect up to 1 in 100 people)
Mood changes (with short-term use), dizziness, tingling in the hands or feet, diarrhoea, vomiting, muscle ache or weakness in the legs.
Not known (frequency cannot be estimated from the available data)
Blood tests may show anaemia (low red cell counts), low counts in white cells or platelets, allergic reactions (may include symptoms of rash, itching, wheals or a serious allergic reaction which causes difficulty breathing or dizziness), changes in blood lipids (cholesterol) or blood sugar, paralysis, seizure, altered vision, pounding heartbeats, changes in ECG (QT prolongation), blood clots in lungs, high or low blood pressure, jaundice, fracture of the spine, thinning of bone, difficulty passing urine, fever, chills, inflammation of lungs or lung disease.
Women
Many of the side effects of PROSTAP 3 are related to the decrease in oestrogen level. Oestrogen level returns to normal after treatment is stopped. Common side effects include hot flushes, mood swings, depression and vaginal dryness. As can happen naturally when women reach the menopause, PROSTAP 3 can cause a small amount of bone thinning. Vaginal bleeding may occur during treatment.
If you have an existing pituitary lesion, there may be an increased risk of loss of blood to the area, which may cause permanent damage. This is very rare (may affect more than 1 in 10,000 people).
Blood sugar levels may be altered during treatment with PROSTAP 3, which may affect control in diabetic patients and require more frequent monitoring.
If you have a blood test your doctor may notice a change in blood lipid (cholesterol) levels or in values for tests on how the liver is working. These changes do not usually cause any symptoms.
Very common (may affect more than 1 in 10 people)
Difficulty sleeping, headaches or hot flushes
Common (may affect up to 1 in 10 people)
Weight changes, mood changes, depression, tingling in hands or feet, dizziness, nausea, joint pain, muscle weakness, breast tenderness, changes in breast size, vaginal dryness, swelling in ankles or skin reactions at the injection site (these include skin hardening, redness, pain, abscesses, swelling, nodules, ulcers and skin damage)
Uncommon (may affect up to 1 in 100 people)
Loss of appetite, changes in blood lipids (cholesterol), altered vision, pounding heartbeats, diarrhoea, vomiting, abnormalities in liver blood tests, hair loss, muscle aches, fever, chills or tiredness
Not known (frequency cannot be estimated from the available data)
Blood tests may show anaemia (low red cell counts), low counts in white cells or platelets, allergic reactions (may include symptoms of rash, itching, wheals or a serious allergic reaction causing difficulty breathing or dizziness), changes in blood sugar, paralysis, blood clots in the lungs, high or low blood pressure, jaundice, abnormalities in liver function, fracture of the spine, seizure, thinning of bone, vaginal bleeding, inflammation of lungs or lung disease.
Side effects when used for breast cancer in combination with either tamoxifen or an aromatase inhibitor
The following side effects have been seen when a similar class of medicine called GnRH analogues (Gonadotrophin Releasing Hormone analogues) has been used for breast cancer in combination with either tamoxifen or an aromatase inhibitor:
Very common (may affect more than 1 in 10 people)
Nausea, feeling very tired, joint and muscle pain, osteoporosis, hot flushes, excessive sweating, difficulty in sleeping, depression, decreased libido, dryness of the vagina, pain during or after sexual intercourse, urinary incontinence, increased blood pressure.
Common (may affect up to 1 in 10 people)
Diabetes, high blood sugar (hyperglycaemia), pain, bruising, redness and swelling at injection site, allergic reaction, bone fractures, blood clot in a blood vessel.
Uncommon (may affect up to 1 in 100 people)
Bleed in the brain, lack of blood supply to the brain or the heart.
Rare (may affect up to 1 in 1000 people)
Change in ECG (QT prolongation)
Children
In the initial phase of treatment, a short-term rise in the sex hormone levels occurs, followed by a fall to values within the prepuberty range. Due to this effect, side effects may occur particularly at the start of treatment.
Common (may affect up to 1 in 10 people):
mood swings
headache
abdominal pain / abdominal cramps
feeling sick / vomiting
acne
vaginal bleeding
spotting
discharge
injection site reactions
Very rare (may affect up to 1 in 10,000 people):
general allergic reactions (fever, rash, itching)
serious allergic reaction which causes difficulty in breathing or dizziness
As with other medicinal products of this class: if you have an existing pituitary lesion, there may be an increased risk of loss of blood to the area, which may cause permanent damage.
Not known (frequency cannot be estimated from the available data):
seizure
inflammation of lungs
lung disease
Notes:
In general, if vaginal bleeding (spotting) occurs with continued treatment (after possible withdrawal bleeding in the first month of treatment), this may be a sign of potential underdosage. Please tell your doctor if vaginal bleeding occurs.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Ingredients
What PROSTAP 3 contains:
The active ingredient in PROSTAP 3 powder is leuprorelin acetate (11.25 mg).
The other ingredients in PROSTAP 3 are: poly (DL-lactic acid), which controls the release of the active ingredient into the body, and mannitol (E421).
The Sterile Solvent contains carmellose sodium, mannitol (E421), polysorbate 80, water for injections and acetic acid, glacial
Acamprosate 333mg tablets, generic of Campral Tablets is indicated as therapy to maintain abstinence in alcohol-dependent patients. It should be combined with counselling.
Ursodeoxycholic Acid Tablets 250mg – Cholurso Tablets, 60 Tablets Introducing Cholurso Tablets the brand name of Ursodeoxycholic Acid Tablets 250mg – Your Solution for Gallstone Management and Liver Health Ursodeoxycholic Acid 250mg Tablets is a cutting-edge pharmaceutical formulation designed to positively influence bile composition, making it a versatile solution for various health concerns. Ursodeoxycholic Acid, […]
Ultimate Surefit Erection Ring Set 15222 – Constrictor Rings For Erectile Dysfunction Experience Confidence and Pleasure with the Ultimate Surefit maintenance ring set – Your Key to Intimate Well-being Introducing the Ultimate Surefit Erection Ring, a premium solution meticulously designed for those seeking to overcome the challenges of erectile dysfunction. Crafted with precision and comfort […]
SureEase Erection Rings 15085 – Constrictor Rings For Erectile Dysfunction Revitalize Your Intimate Moments with SureEase Erection Rings – Precision for Confidence and Pleasure SureEase Erection Rings are the discreet yet powerful solution designed to rekindle confidence and elevate pleasure for individuals facing challenges with erectile dysfunction. Crafted with precision, these constrictor rings provide targeted […]
SomaErect Touch II 15013 – Vacuum Pump Erection Device Introducing SomaErect Touch II 15013 – Redefining Intimacy with Advanced Vacuum Pump Technology The SomaErect Touch II 15013 is an innovative vacuum pump erection device, meticulously engineered to provide a discreet, effective, and user-friendly solution for individuals dealing with erectile dysfunction. Embrace confidence and intimacy with […]
Nardil contains the active ingredient phenelzine, which belongs to a group of medicines called monoamine oxidase inhibitors, or MAOIs.
Nardil is used to treat certain types of depression. It works by changing the way messages are sent from one nerve to another in the brain. Nardil is especially helpful when:
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
1 review for Prostap Injection 3.75mg DCS – Leuprorelin Injection, 1 Pack
Diane (verified owner) –
Julie Cutbush –
Dear Diane, we appreciate your support.